CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
IMVAMUNE®biological
Likely dose
IMVAMUNE® 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03472014
NCT03472014Phase 4Completed
CompareCT.gov

A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus

Bavarian Nordic·interventional·Posted Mar 21, 2018·Updated Aug 19, 2020

In Brief

A Phase 4 clinical trial evaluating IMVAMUNE® for Vaccination. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccination
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 21, 2018
Enrollment StartApr 22, 2010
Primary CompletionNov 14, 2014
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.3 years ago

Interventions

IMVAMUNE®biological

IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose